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Objective. To assess the vascular effects of high-dose androgen
treatment in genetic females.
Background. Male gender is an independent risk factor for
coronary artery disease, suggesting either a protective effect of
estrogens and/or a deleterious effect of androgens. We have
recently demonstrated that androgen deprivation is associated
with enhanced vascular reactivity in adult men, however, the
effects of androgen excess on vascular function in humans has not
been reported previously.
Methods. We studied vascular reactivity in two groups of
genetic females: 12 female-to-male transsexuals receiving long-
term high-dose androgens, and 12 healthy female control subjects,
matched for age and smoking history. Using external vascular
ultrasound, brachial artery diameter was measured at rest, after
flow increase (leading to flow-mediated dilatation [FMD], which
depends on normal endothelial function) and after sublingual
nitroglycerin (NTG), an endothelium-independent dilator.
Results. Testosterone levels were higher (15.2 6 8.7 vs. 1.9 6
1.3 mmol/L, p < 0.001) and high-density lipoprotein cholesterol
levels were lower (1.2 6 0.2 vs. 1.6 6 0.4 mmol/L, p 5 0.02) in the
transsexuals compared with the control subjects. In each group,
nine of 12 subjects were current or ex-smokers, leading to
impaired FMD in both groups (5.1 6 3.7% in the transsexuals vs.
6.9 6 4.1% in controls, p 5 0.28). The NTG response was
significantly decreased in the transsexuals (15.9 6 4.9% vs. 22 6
5.8% in controls, p 5 0.01), independent of the effects of age,
cholesterol or vessel size.
Conclusions. Long-term treatment with high-dose androgens is
associated with impaired vascular reactivity in genetic females,
consistent with a deleterious effect of androgen excess on arterial
physiology.
(J Am Coll Cardiol 1998;32:1331–5)
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An important gender difference exists in the incidence of
cardiovascular disease, with males being at higher risk than
females (1). Many epidemiologic and experimental studies
have addressed the possible protective effects of estrogens,
including lipid-lowering, antioxidant and direct arterial wall
benefits (2–4).
Less well tested, however, is the possibility that androgens
may have a detrimental effect on the vessel wall. In recent
work, Adams et al. (5) have found that testosterone adminis-
tration increases atheroma in cholesterol-fed female monkeys,
and Hutchison et al. (6) have demonstrated androgen-induced
endothelial dysfunction in a rabbit model of atherosclerosis. In
humans, we have recently found that androgen deprivation by
medical and/or surgical castration is associated with enhanced
vascular reactivity in adult men (7). States of androgen excess,
however, are relatively rare in humans, and to date no studies
on the effects of high-dose androgens on vascular function
have been reported.
Impaired vascular reactivity is an important early event in
atherogenesis (8) and may determine dynamic plaque behavior
in patients with advanced coronary artery disease (9). We have
therefore studied endothelium and smooth muscle–dependent
vascular responses in a relatively uncommon group of subjects
treated with long-term, high-dose androgen therapy; that is,
female-to-male transsexual adults.
Methods
Subjects. We investigated 12 consecutively recruited
female-to-male transsexuals aged 33 6 5 (range 26 to 46)
years, who had been receiving high-dose androgen therapy for
at least 2 months. Their duration of hormonal therapy was
38 6 52 (range 2 to 177) months. For each transsexual subject,
a healthy female control was also investigated; age and active
tobacco smoking history were carefully matched between the
groups, owing to the known influence of these factors on
vascular reactivity (10,11). The control subjects were aged 31 6
7 (range 26 to 41) years. In two cases where subjects could be
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studied before and after commencing androgen therapy, the
subjects served as their own controls; controls for the other 10
transsexuals were recruited from among hospital staff and
community volunteers. No subjects had a history of clinical
atherosclerosis, hypertension or diabetes mellitus, and none
was taking regular cardiovascular medications.
Of the 12 transsexual subjects, 10 were treated with testos-
terone depot implants (200 to 800 mg) and 2 were receiving
regular intramuscular testosterone ester injections. Four had
had hysterectomies performed, in two cases with ovariectomy
(these latter two subjects had been taking piperazine estrone
sulfate 2.5 mg/day since their ovariectomy), and two other
subjects had undergone gender reassignment surgery 2 to 12
years before their study visit. One had a history of schizophre-
nia and was taking risperidone (5 mg daily). The other 11
transsexuals were medically well, as were the control subjects.
All subjects gave informed consent, and the study was ap-
proved by our institutional committee on ethical practice.
Study design. Each patient had at least one visit to the
study center, during which a history was taken, supine resting
blood pressure was measured and a nonfasting blood sample
was taken for estimation of total and high-density lipoprotein
(HDL) cholesterol (using Hitachi 747 autoanalyzer [Boehr-
inger Mannheim, Castle Hill, New South Wales, Australia]; the
HDL fraction levels after precipitation with phosphotungstate-
magnesium), and total and free testosterone levels (using
radioimmunoassay).
Arterial reactivity was measured in the right brachial artery
using external vascular ultrasound, as described in detail
elsewhere (7,10). In brief, flow-mediated dilatation (FMD) was
measured as the change in arterial diameter during a condition
of reactive hyperemia, and smooth muscle–dependent re-
sponse was measured as the change in diameter after a 400-mg
spray of sublingual nitroglycerin (NTG). The accuracy and
reproducibility of this method have previously been estab-
lished, with a coefficient of variation for measurement of FMD
in our laboratory of approximately 2% (8,12). The degree of
hyperemia is calculated from Doppler-derived flow measure-
ments during the condition of reactive hyperemia, compared
with rest flow (11). Flow-mediated dilatation measured in this
way is endothelium dependent, as it is predominantly due to
nitric oxide release by the endothelium (13). This response in
the brachial artery correlates well with coronary endothelial
function (14). The NTG-induced vasodilatation is endothelium
independent and reflects smooth muscle function, being me-
diated via the activation of guanylate cyclase and consequent
increase in intracellular cyclic GMP. Ultrasound analysis was
performed in each case by two independent observers who had
no knowledge of each subject’s identity or the stage of each
series of scans, as reported previously (12).
Statistics. Descriptive data are expressed as mean value 6
SD. The two groups of subjects (transsexuals and controls)
were compared by independent samples t tests. The prospec-
tively defined primary end points of this study were FMD and
NTG responses. All other t test results were adjusted for
multiple comparisons using Hochberg’s modification of the
Bonferroni procedure (15). The determinants of FMD and
NTG-induced dilatation were assessed by univariate and mul-
tivariate linear regression analyses with age, vessel size, total or
HDL cholesterol and androgen therapy being entered as the
independent variables. Statistical significance was inferred at a
two-sided p value ,0.05.
Results
Baseline characteristics. The female-to-male transsexuals
and control subjects were well matched for age, smoking
history, total cholesterol level, blood pressure and resting
blood flow (Table 1). The average pack/year cigarette con-
sumption in the current and former smokers was similar in
each group; 13 6 8 for the transsexuals and 13 6 7 for control
subjects. In the androgen-treated genetic females, HDL cho-
lesterol was lower, vessel size was larger and testosterone levels
were higher. In the transsexual subjects, serum estradiol levels
were 144 6 39 pmol/L (normal range for premenopausal
women, 75 to 1300 pmol/L), progesterone levels were 1.04 6
0.2 nmol/L (normal range, ,2 to 90 nmol/L), follicle stimulat-
ing hormone levels were 15.3 6 18.6 IU/L (normal range, 1.5
to 20 IU/L) and sex hormone binding globulin levels were
29.9 6 9.6 nmol/L (normal range, 15 to 140 nmol/L).
Abbreviations and Acronyms
FMD 5 flow-mediated dilatation
HDL 5 high-density lipoprotein
NTG 5 nitroglycerin
Table 1. Baseline Characteristics and Vascular Study Results in
Female-to-Male Transsexuals (n 5 12) and Genetic Female Control
Subjects (n 5 12)
Characteristic Transsexuals Controls p Value*
Age (yr) 33 6 6 31 6 6 0.80
Smoking† 6/3/3 6/3/3 —
Testosterone (nmol/L)‡ 15.2 6 8.7 1.9 6 1.3 , 0.001
Free testosterone (pmol/L)‡ 225 6 145 38 6 29 , 0.001
Total cholesterol (mmol/L) 5.2 6 0.9 5.1 6 1.0 0.80
HDL cholesterol (mmol/L) 1.2 6 0.2 1.6 6 0.4 0.02
Baseline flow (mL/min) 47 6 22 40 6 31 0.80
Vessel size (mm) 3.8 6 0.3 3.1 6 0.4 , 0.001
SBP (mm Hg) 117 6 12 124 6 17 0.64
DBP (mm Hg) 74 6 11 73 6 9 0.80
FMD (%) 5.1 6 3.7 6.9 6 4.1 0.28
NTG (%) 15.9 6 4.9 22 6 5.8 0.01
Hyperemia (%) 571 6 280 674 6 422 0.80
Data are presented as mean 6 SD. DBP 5 diastolic blood pressure; FMD 5
flow-mediated dilatation; NTG 5 nitroglycerin-induced dilatation; HDL 5 high
density lipoprotein; SBP 5 systolic blood pressure. *p Values adjusted for
multiple comparisons (see Methods). †Smoking history; current/former/never
smoker. ‡Normal ranges for healthy male adults are 11–35 nmol/L for total and
170–510 pmol/L for free testosterone.
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Vascular reactivity. The degree of reactive hyperemia after
cuff deflation (the stimulus to FMD) was .500% in both
groups. In response to this flow increase, FMD was 5.1 6 3.7%
in the female-to-male transsexuals and 6.9 6 4.1% in the
control subjects (p 5 0.28) (Fig. 1). In contrast, FMD mea-
sured by the same technique in healthy young female non-
smokers is approximately 10% (9,10). The NTG response,
unaffected by cigarette smoking (8), was significantly impaired
in the transsexuals (15.9 6 4.9% vs. 22 6 5.8% in the controls;
p 5 0.01), consistent with decreased smooth muscle dilator
function. There was no significant correlation between NTG
response and the recorded blood pressure (p . 0.3). In the two
subjects studied before and after androgen therapy was com-
menced, NTG-induced dilatation decreased from 25% to 18%
in one, and 22% to 16% in the other, after 2 to 4 months of
hormone treatment. In the same subjects, FMD declined from
11% to 2% in one, but was unchanged in the other (a heavy
ex-smoker).
On multivariate analysis, FMD was not related to androgen
therapy, vessel size, cholesterol or testosterone levels. The
NTG response, however, was significantly impaired in the
transsexuals (partial correlation coefficient 5 20.65, p 5 0.03)
independent of the effects of age, vessel size or total choles-
terol levels. In this multivariate model, the multiple r value was
0.80, the F value was 4.32 and the significance of F was 0.02.
When HDL cholesterol rather than total cholesterol was
entered into the multivariate model, HDL levels were not
independently related to the NTG response.
Discussion
The greater predisposition of males to coronary artery
disease has focused recent attention on the role of sex hor-
mones in atherogenesis. These steroids may have complex
vascular effects, including those on arterial structure and
function, as well as on coagulation pathways and vasoactive
factors. Indeed, many studies have suggested that estrogens
may be atheroprotective agents, via lipid-lowering, antioxidant
and/or direct vascular function effects (16). In contrast, rela-
tively little has been written about the vascular effects of
androgens in human females or males. In this study, we report
the effects of long-term high-dose androgens in humans for the
first time in an uncommon group of subjects; female-to-male
transsexuals. Although the group is small and the measure-
ment of endothelial function confounded by a high proportion
of smokers, vascular reactivity was impaired in the transsexual
subjects, consistent with a deleterious effect of androgen excess
on arterial physiology.
Previous studies: androgens and vascular effects. In acute
infusion studies, testosterone in supraphysiologic doses ap-
pears to act as a direct vasodilator and may be associated with
relief of angina pectoris in men (17), possibly via K1 channel–
related coronary vasorelaxant effects (18). The more chronic
effects of androgens, however, have only been examined in a
variety of animal models, with often conflicting results (19–21).
The long-term vascular effects of androgens in humans have
been difficult to study, in part because there is no clinical
syndrome or phenotype for androgen excess in men. By
contrast, estrogen supplementation (postmenopausal women
taking hormone replacement) and deficiency (premature
menopause) have been much more common and therefore
more amenable to investigation. Recently, we studied a group
of men with long-term complete androgen deprivation as
therapy for prostate cancer; in these men, medical and/or
surgical castration was associated with enhanced vascular
reactivity, consistent with a deleterious effect of normal male
levels of testosterone on the vessel wall (7). Furthermore, we
and others have found vascular reactivity to be enhanced in
male-to-female transsexuals who were taking high-dose estro-
gens (22,23). This latter observation may be due to the effects
of the estrogen excess and/or the androgen deprivation due to
such treatment. Recently, Birdsall et al. (24) have demon-
strated more severe and extensive coronary artery disease in
women with polycystic ovarian syndrome compared with con-
trols, however, this condition is characterized by other poten-
Figure 1. Flow-mediated and nitroglycerin-induced dilatation in 12
genetic females receiving high-dose androgens (female-to-male trans-
sexuals) and in 12 female control subjects. The y axes refer to percent
change in brachial artery diameter. GTN 5 glyceryl trinitrate (nitro-
glycerin).
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tially pro-atherogenic metabolic abnormalities (e.g., insulin
resistance, obesity), in addition to mild hyperandrogenism. In
the current study, we have examined some of the vascular
effects of androgen excess per se, particularly finding a de-
crease in smooth muscle–dependent vasodilator response in
two subjects studied serially with a reproducible technique (11),
before and after the commencement of androgen therapy.
Mechanism. The mechanism whereby androgens might
lead to impaired vascular reactivity is unknown. In some
studies, testosterone therapy has been shown to decrease HDL
cholesterol (25), as was observed in our current study. Overall,
however, the data concerning androgens and lipoprotein pro-
files have not consistently shown any deleterious effect (26). It
is possible that there are direct effects of androgen on the
vessel wall, as steroid receptors exist in the vasculature (27).
The mechanism whereby androgens may be associated with
larger arterial size in genetic females is also uncertain, how-
ever, testosterone’s activity as a direct smooth muscle vasore-
laxant (18) may be important in this regard. In the current
study, the impairment in vascular reactivity observed in the
transsexual subjects was independent of the effects of vessel
size.
Epidemiologic data. Many studies have confirmed the in-
creased prevalence of premature atherosclerotic disease in
men (1,28). Within each gender, however, there has been no
consistent association between androgen levels within the
sex-specific physiologic ranges and cardiovascular event rates.
Although most cross-sectional studies suggest an inverse cor-
relation between androgen levels and cardiovascular event
rates in men, in prospective studies there has been no signifi-
cant correlation demonstrated between testosterone levels and
coronary disease in men (29) or between androgen levels and
arterial disease in women (30). Therefore, the large difference
in androgen levels between genders accounts for most of the
gender difference in cardiovascular risk, and the small differ-
ences that exist within normal populations of men or women
are of relatively minor significance.
Study limitations. A limitation of the current study is its
cross-sectional and nonrandomized design. Although these
relatively small groups should have been similar, as subjects
were closely matched for age, smoking status, blood pressure
and absence of other known vascular risk factors, it is still
possible that unmeasured differences between groups (other
than their hormonal status) were present (e.g., passive smoke
exposure or homocysteine levels). A prospective study of the
effects of long-term androgen therapy in women would be
difficult, however, due to the limited access to transsexuals who
have not already received some treatment and to the sensitiv-
ities of recruiting and investigating subjects during their period
of gender transition. Two of our 12 subjects were studied
serially and showed results similar to those of the overall
group. Furthermore, the high prevalence of smoking in the
transsexual subjects (also noted previously by Van Kesteren et
al. [31]) importantly reduced the power of the study to detect
any significant difference in FMD between groups, as smoking
(current and former) is a major cause of endothelial dysfunc-
tion (8,32).
As impaired vascular reactivity is important both in early
atherogenesis and determining plaque behavior late in the
natural history of atherosclerosis (7,8), our observations of
decreased arterial vasodilator responses might have adverse
prognostic implications for genetic females taking androgens,
however, long-term clinical follow-up of a large cohort of such
female-to-male transsexual subjects would be required to
assess this possibility.
Conclusion. Long-term therapy with high-dose androgens
is associated with impaired vascular reactivity in genetic fe-
males, independent of the effects of androgens on lipoprotein
levels or vessel size. Although interactions between sex steroids
and the vessel wall are complex, these data are consistent with
a deleterious effect of androgen excess in genetic females.
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